



SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)

April 10, 2018

JERSEY CITY, N.J., April 10, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 21-24, 2018, in Madrid, Spain. SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

Title: *In Vitro* Activity of SCY-078, a Novel IV/Oral Glucan Synthase Inhibitor, against *Aspergillus* spp., Alone or in Combination with other Antifungal Therapies

Presenter: Mahmoud Ghannoum PhD

Date and Time: Saturday, April 21, from 15:30-16:30 CET

Poster Presentation #: PO164

Session: *Aspergillus* in the laboratory

Title: Activity of SCY-078 and comparators against a collection of *Aspergillus* spp. including cryptic species and Cyp51A mutants

Presenter: Ana Alastruey-Izquierdo PhD

Date and Time: Saturday, April 21, from 15:30-16:30 CET

Poster Presentation #: PO165

Session: *Aspergillus* in the laboratory

Title: SCY-078 Demonstrates Antifungal Activity Against *Pneumocystis* in a Prophylactic Murine Model of *Pneumocystis* Pneumonia

Presenter: Stephen Barat PhD

Date and Time: Sunday, April 22, from 13:30-14:30 CET

Poster Presentation #: P1226

Session: Update on *Pneumocystis*

The ECCMID 2018 posters will be available on the SCYNEXIS website following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The [SCYNEXIS team](#) has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, [SCY-078](#), is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by *Candida* and *Aspergillus* species. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations

Susan Kim

Argot Partners

Tel: 212-203-4433

susan@argotpartners.com

Media Relations

George E. MacDougall

MacDougall Biomedical Communications

Tel: 781-235-3093

george@macbiocom.com

Cision View original content: <http://www.prnewswire.com/news-releases/scynexis-to-present-scy-078-data-at-the-28th-european-congress-of-clinical-microbiology-and-infectious-disease-eccmid-300625304.html>

SOURCE SCYNEXIS, Inc.